ADC Therapeutics (ADCT) Gross Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted Gross Margin of 83.37% for Q1 2026, down 10.05% sequentially from 92.68% in Q3 2025, and down 768.0% YoY from 12.48% in Q1 2025.
ADC Therapeutics (ADCT) Gross Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics has reported Gross Margin for 6 years, with the latest figure at 83.37% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | 89.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.07% |
| Mar 31, 2026 | 83.37% |
| Sep 30, 2025 | 92.68% |
| Jun 30, 2025 | 95.56% |
| Mar 31, 2025 | 91.05% |
| Sep 30, 2024 | 95.39% |
| Jun 30, 2024 | 93.01% |
| Mar 31, 2024 | 86.10% |
| Sep 30, 2023 | 97.47% |
| Jun 30, 2023 | 93.16% |
| Mar 31, 2023 | 96.89% |
| Sep 30, 2022 | 98.30% |
| Jun 30, 2022 | 86.89% |
| Mar 31, 2022 | 98.86% |
| Sep 30, 2021 | 96.18% |
| Jun 30, 2021 | 96.78% |